Top 10 Companies in the (R)-4‑Fluorophenylglycine (CAS 93939‑74‑3) Market (2026): Market Leaders Driving Global Pharmaceutical Innovation

MARKET INSIGHTS

Global (R)-4-Fluorophenylglycine (CAS 93939‑74‑3) market size was valued at USD 28.4 million in 2025. The market is projected to grow from USD 30.1 million in 2026 to USD 52.7 million by 2034, exhibiting a CAGR of 6.4 % during the forecast period.

(R)-4-Fluorophenylglycine (CAS 93939‑74‑3) is a chiral amino acid derivative characterized by a fluorine substituent at the para position of the phenyl ring. This enantiomerically pure compound serves as a critical building block in pharmaceutical synthesis, particularly in the production of active pharmaceutical ingredients (APIs) where stereochemical precision is paramount. Its unique structural properties make it highly valuable in peptide chemistry, agrochemical development, and the manufacture of biologically active molecules.

The market is witnessing steady growth driven by rising demand for enantioselective synthesis in drug development and increasing adoption of fluorinated compounds in medicinal chemistry. Furthermore, the expanding pipeline of chiral pharmaceutical products globally continues to reinforce demand for high‑purity intermediates such as (R)-4-Fluorophenylglycine. Key suppliers operating in this space include Alfa Aesar, Sigma‑Aldrich (Merck KGaA), and various specialized fine chemical manufacturers across Asia‑Pacific and Europe.

(R)-4-Fluorophenylglycine (CAS 93939‑74‑3) Market – View in Detailed Research Report

Top 10 Companies in the (R)-4‑Fluorophenylglycine Market

---

10️⃣ Shanghai Trustin Chemical Co., Ltd. (China)

Headquarters: Shanghai, China
Key Offering: Bulk pharmaceutical‑grade (R)-4‑Fluorophenylglycine

Shanghai Trustin has established a reputation for delivering high‑purity chiral intermediates at competitive cost. Its integrated production line incorporates advanced enzymatic resolution, ensuring consistent enantiomeric excess and meeting strict regulatory requirements. The company’s focus on process scale‑up and supply‑chain robustness supports API manufacturers worldwide.

Sustainability & Growth Initiatives:

• Investment in biocatalytic reactors to reduce solvent use by 35 %.
• Implementation of ISO 9001 and ISO 14001 certifications to align with global quality and environmental standards.
• Expansion of CMO partnerships across Asia‑Pacific to secure long‑term contracts.

---

9️⃣ Biosynth AG (Switzerland)

Headquarters: Winterthur, Switzerland
Key Offering: Custom synthesis of high‑purity (R)-4‑Fluorophenylglycine

Biosynth AG leverages its recent acquisition of Carbosynth to broaden its amino‑acid portfolio. The firm emphasizes GMP compliance and rigorous impurity profiling, positioning it as a preferred partner for high‑value API development. Its state‑of‑the‑art chiral separation facilities enable rapid turnaround for bespoke projects.

Sustainability & Growth Initiatives:

• Adoption of continuous flow chemistry to increase throughput and reduce waste.
• Collaboration with EU research consortia to develop next‑generation chiral catalysts.
• Commitment to achieving net‑zero emissions by 2035.

---

8️⃣ Finetech Industry Limited (China)

Headquarters: Shanghai, China
Key Offering: High‑purity (R)-4‑Fluorophenylglycine for API synthesis

Finetech Industry has rapidly scaled its production capacity by integrating asymmetric synthesis modules. The company’s focus on process optimization has resulted in a 25 % reduction in production costs while maintaining superior optical purity. Its strong relationships with major pharmaceutical manufacturers provide a stable demand base.

Sustainability & Growth Initiatives:

• Implementation of closed‑loop solvent recycling systems.
• Investment in renewable energy sources for manufacturing facilities.
• Participation in China’s “Green Chemistry” national program.

---

7️⃣ Combi-Blocks Inc. (USA)

Headquarters: San Diego, California, USA
Key Offering: Custom chiral building blocks for peptide therapeutics

Combi-Blocks focuses on delivering enantiomerically pure intermediates tailored for peptide‑based drug discovery. The company’s proprietary enzyme‑based resolution platform delivers high enantiomeric excess with minimal by‑products. Its strong GMP framework and quality certifications make it a trusted partner for biopharma R&D.

Sustainability & Growth Initiatives:

• Development of enzyme cocktails that reduce reaction temperatures, lowering energy consumption.
• Collaboration with academic institutions to explore sustainable catalyst design.
• Adoption of digital process monitoring to enhance transparency.

---

6️⃣ Amino Acids Services (France)

Headquarters: Lyon, France
Key Offering: Rare chiral amino‑acid production for specialty markets

As an independent specialist, Amino Acids Services supplies high‑purity (R)-4‑Fluorophenylglycine to niche segments such as agrochemicals and research laboratories. The company’s focus on quality and regulatory compliance ensures that it meets the stringent demands of European markets.

Sustainability & Growth Initiatives:

• Use of biodegradable solvents in synthesis.
• Engagement in EU Horizon 2020 projects for sustainable chemistry.
• Implementation of lean manufacturing practices to reduce waste.

---

5️⃣ Tokyo Chemical Industry Co., Ltd. (Japan)

Headquarters: Tokyo, Japan
Key Offering: High‑purity (R)-4‑Fluorophenylglycine for API and fine‑chemical markets

TCI leverages its extensive experience in chiral synthesis to provide reliable supply of (R)-4‑Fluorophenylglycine. The company’s rigorous quality control processes and long‑term contracts with global API manufacturers underpin its market position.

Sustainability & Growth Initiatives:

• Investment in green chemistry initiatives to lower hazardous waste.
• Participation in Japan’s “Eco‑Industrial Complex” program.
• Use of renewable energy for production facilities.

---

4️⃣ Henan DaKen Chemical Co., Ltd. (China)

Headquarters: Zhengzhou, Henan, China
Key Offering: Bulk supply of (R)-4‑Fluorophenylglycine for API production

Henan DaKen has expanded its capacity through strategic investments in asymmetric synthesis technology. The firm’s focus on scalability and cost efficiency has attracted a growing portfolio of API manufacturers in the Asia‑Pacific region.

Sustainability & Growth Initiatives:

• Implementation of energy‑efficient reactors.
• Adoption of zero‑waste policies in production lines.
• Collaboration with local universities for talent development.

---

3️⃣ Changzhou Sinobioway Organic Chemical Co., Ltd. (China)

Headquarters: Changzhou, Jiangsu, China
Key Offering: High‑purity (R)-4‑Fluorophenylglycine for pharmaceutical intermediates

Changzhou Sinobioway’s integrated manufacturing facilities support continuous production of chiral intermediates. The company’s emphasis on process optimization has enabled it to maintain consistent quality across large batches.

Sustainability & Growth Initiatives:

• Use of renewable feedstocks for aromatic synthesis.
• Implementation of water‑recycling systems.
• Participation in China’s “Green Chemistry” certification program.

---

2️⃣ Qingdao Sigma Chemical Co., Ltd. (China)

Headquarters: Qingdao, Shandong, China
Key Offering: (R)-4‑Fluorophenylglycine for pharmaceutical and agrochemical applications

Qingdao Sigma Chemical combines advanced chiral synthesis with rigorous impurity profiling to deliver high‑purity intermediates. The firm’s focus on process robustness has positioned it as a reliable supplier for both domestic and international customers.

Sustainability & Growth Initiatives:

• Adoption of green solvents in synthesis processes.
• Implementation of waste‑to‑energy projects.
• Engagement in regional sustainability forums.

---

1️⃣ Merck KGaA (Germany)

Headquarters: Darmstadt, Germany
Key Offering: Premium (R)-4‑Fluorophenylglycine for high‑value API development

Merck KGaA’s reputation for quality and innovation underpins its position as a leading supplier of chiral intermediates. The company’s extensive R&D capabilities enable it to tailor synthesis routes to meet the evolving needs of pharmaceutical developers.

Sustainability & Growth Initiatives:

• Investment in biocatalytic platforms to reduce carbon footprint.
• Commitment to achieving carbon neutrality across the supply chain by 2030.
• Active participation in EU sustainability initiatives.

---

Download FREE Sample Report: (R)-4-Fluorophenylglycine (CAS 93939‑74‑3) Market – View in Detailed Research Report

Get Full Report: (R)-4-Fluorophenylglycine (CAS 93939‑74‑3) Market – View in Detailed Research Report

Market Outlook

Over the next decade, the (R)-4‑Fluorophenylglycine market will continue to expand, driven by the growing emphasis on enantiomerically pure compounds in API synthesis and the rising pipeline of chiral drugs. The transition to greener manufacturing processes, coupled with advances in enzymatic resolution, will sustain competitive pricing while maintaining high purity standards. Market participants that invest early in scalable biocatalytic infrastructure and secure robust supply chains will be best positioned to capture the projected growth.

Future Trends

• Adoption of continuous flow biocatalysis will streamline production and reduce batch variability.
• Integration of AI‑driven process optimization will accelerate development of new chiral catalysts.
• Regulatory focus on sustainability will favor manufacturers that demonstrate low‑carbon footprints and zero‑waste operations.
• Expansion of contract manufacturing organizations in emerging markets will broaden the customer base for high‑purity intermediates.
• Emerging therapeutic modalities such as PROTACs and peptide conjugates will intensify demand for specialized chiral building blocks.